For ALK+ NSCLC, Thomas10 also found no evident difference between TKI and CNS RT + TKI groups for the time to intracranial progression (18.1 vs. 21.8 months, p = 0.65). The gene discussed is ALK; the disease is non-small cell lung carcinoma.